Delivery Order SPE2DB22D1017-SPE2DB25FF3WS

Award Date 1/24/25
Potential Completion Date 1/27/25
Potential Value $1.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,942.86, is for the delivery of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The award is a firm fixed-price delivery order contract with a completion date of June 28, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,632.54, is for the delivery of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a medical product. The contract is a delivery order with a firm fixed price, and the ultimate completion date is February 19, 2025. The contract is not designated with a set-aside requirement, indicating open competition....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,668.42, is a Firm Fixed Price Delivery Order for the pharmaceutical product "MOUNJARO 5 MG/0.5 ML PEN 0.5ML". The contract has an ultimate completion date of May 29, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,632.35, is for the delivery of the pharmaceutical product MOUNJARO 5 MG/0.5 ML PEN 0.5ML. The contract has an ultimate completion date of January 2, 2025 and is a firm fixed-price delivery order. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,839.97, is for the delivery of MOUNJARO 12.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of November 15, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The award, with a ceiling value of $5,316.98, is for the delivery of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical to provide a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,990.32 firm-fixed-price delivery order is for the supply of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of April 27, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,130.40 firm fixed-price delivery order is for the supply of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of November 18, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,099.87, is a delivery order for the supply of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of January 6, 2025 and a firm fixed price pricing type. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $1,315.00, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) for the supply of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. This delivery order has a firm fixed-price pricing type and an ultimate completion date of November 5, 2024. The contract does not have a...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB25FF3WS
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,642.51, is a firm-fixed-price delivery order for the medical product "MOUNJARO 5 MG/0.5 ML PEN 0.5ML". The contract has an ultimate completion date of January 27, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This award is not designated with a set-aside requirement, indicating open competition.

Generated 4/25/25, 10:11 AM